PlainRecalls
FDA Drug Moderate Class II Terminated

Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distributed by Hikma Berkeley Heights, NJ 07922, NDC 0143-9299-01

Reported: January 4, 2023 Initiated: December 16, 2022 #D-0090-2023

Product Description

Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distributed by Hikma Berkeley Heights, NJ 07922, NDC 0143-9299-01

Reason for Recall

Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

Details

Units Affected
13,760 vials
Distribution
USA Nationwide
Location
Cherry Hill, NJ

Frequently Asked Questions

What product was recalled?
Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distributed by Hikma Berkeley Heights, NJ 07922, NDC 0143-9299-01. Recalled by Hikma Pharmaceuticals USA Inc.. Units affected: 13,760 vials.
Why was this product recalled?
Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 4, 2023. Severity: Moderate. Recall number: D-0090-2023.